scorecardresearch
Add as a preferred source on Google
Saturday, April 11, 2026
TopicCadila Healthcare

Topic: Cadila Healthcare

Cadila looks to double its vaccine production as India battles to contain second Covid wave

The Indian drugmaker expects regulatory approval for its vaccine against Covid-19 by June. Efficacy readings from its last stage of clinical trials are expected in May.

Cadila to boost Covid vaccine production capacity by 70% if it passes human trials

Cadila is looking to hire contract manufacturers for additional 50-70 million doses of its vaccine, on top of 100 million that will come from its own capacity.

Kraft Heinz to sell some of its Indian businesses to Zydus for Rs 46 billion

Kraft to sell Complan, Glucon D & Nycil, among others to Zydus Wellness, in a deal estimated to be worth $625 million.

On Camera

What can be expected from the ongoing talks in Islamabad? Odds of resolution remain slim

The initial ceasefire functioned less as a resolution and more as a pause—an opportunity for both sides to recalibrate, while claiming victory.

India bond yields rise as RBI moves to drain liquidity, lift overnight rates

New Delhi: India’s sovereign bond yields rose after the central bank announced its first step this year to drain cash from the banking system,...

Army promotes Col Purohit, acquitted in 2008 Malegaon blast case, to Brigadier; to not retire yet

This means he will serve Indian Army for a minimum of another 2 years as Brigadier, unless he picks up the next rank of Major General.

China insulated itself against energy shocks. India is ‘all talk, no walk’

China patiently invested capital, skill and technology in coal gasification. Unlike it, we won’t move from words to action. As crude prices decline, we lose interest.